Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINTS: Neoadjuvant paclitaxel polymer micelles + cisplatin + camrelizumab in locally advanced esophageal squamous cell carcinoma
ChiCTR2300073898Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Pathologic complete response rate (pCR). Started Jul 2023; status: recruiting.
02
Drugs
camrelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300073898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073898.